Diana Elizabeth Tullis




As the Director of the Toronto Adult Cystic Fibrosis (CF) Clinic at St. Michael’s Hospital, Dr. Tullis is responsible for the care of 450 adults with CF. Dr. Tullis is a Professor of Medicine at the University of Toronto, the Respirology Division Head at St. Michael’s Hospital, and an Associate Scientist in the Li Ka Shing Knowledge Institute. She is the Cystic Fibrosis Canada Chair in Adult CF Research.

Dr. Tullis has published over 100 articles and book chapters and has lectured nationally and internationally on issues related to CF in adults. She has had 25 years of experience with CF clinical care. She was the Chair of the Clinic Subcommittee of the Medical/Scientific Advisory Board of Cystic Fibrosis Canada from 2005-2011 and in 2010 was a Coach for the Adult Quality Improvement Program run by the American Cystic Fibrosis Foundation.

Recent Publications

  1. Zikic, A, Ratjen, F, Shaw, M, Tullis, E, Waters, V. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2022; :. doi: 10.1016/j.jcf.2022.05.010. PubMed PMID:35650003 .
  2. Gong, J, He, G, Wang, C, Bartlett, C, Panjwani, N, Mastromatteo, S et al.. Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. NPJ Genom Med. 2022;7 (1):28. doi: 10.1038/s41525-022-00299-9. PubMed PMID:35396391 PubMed Central PMC8993824.
  3. Sutharsan, S, McKone, EF, Downey, DG, Duckers, J, MacGregor, G, Tullis, E et al.. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022;10 (3):267-277. doi: 10.1016/S2213-2600(21)00454-9. PubMed PMID:34942085 .
  4. Barry, PJ, Mall, MA, Álvarez, A, Colombo, C, de Winter-de Groot, KM, Fajac, I et al.. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021;385 (9):815-825. doi: 10.1056/NEJMoa2100665. PubMed PMID:34437784 PubMed Central PMC8982185.
  5. Derichs, N, Taylor-Cousar, JL, Davies, JC, Fajac, I, Tullis, E, Nazareth, D et al.. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. J Cyst Fibros. 2021;20 (6):1018-1025. doi: 10.1016/j.jcf.2021.07.015. PubMed PMID:34419414 .
  6. Lin, YC, Keenan, K, Gong, J, Panjwani, N, Avolio, J, Lin, F et al.. Correction to: Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth. Genet Med. 2021;23 (11):2235-2236. doi: 10.1038/s41436-021-01281-z. PubMed PMID:34389817 PubMed Central PMC8553623.
  7. Zemanick, ET, Taylor-Cousar, JL, Davies, J, Gibson, RL, Mall, MA, McKone, EF et al.. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021;203 (12):1522-1532. doi: 10.1164/rccm.202102-0509OC. PubMed PMID:33734030 PubMed Central PMC8483230.
  8. Tullis, P. How ecstasy and psilocybin are shaking up psychiatry. Nature. 2021;589 (7843):506-509. doi: 10.1038/d41586-021-00187-9. PubMed PMID:33505033 .
  9. Lin, YC, Keenan, K, Gong, J, Panjwani, N, Avolio, J, Lin, F et al.. Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth. Genet Med. 2021;23 (5):927-933. doi: 10.1038/s41436-020-01073-x. PubMed PMID:33500570 PubMed Central PMC8105168.
  10. McKone, EF, DiMango, EA, Sutharsan, S, Barto, TL, Campbell, D, Ahluwalia, N et al.. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021;20 (2):234-242. doi: 10.1016/j.jcf.2020.11.003. PubMed PMID:33339768 .
Search PubMed

Affiliations & Other Activities

  • Head, Division of Respirology, St. Michael’s Hospital
  • The Cystic Fibrosis Canada Chair in Adult Cystic Fibrosis Research, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto